Apolipoprotein A-i As A Candidate Serum Marker For The Response To Lithium Treatment In Bipolar Disorder.

dc.creatorSussulini, Alessandra
dc.creatorDihazi, Hassan
dc.creatorBanzato, Claudio Eduardo Muller
dc.creatorArruda, Marco Aurelio Zezzi
dc.creatorStühmer, Walter
dc.creatorEhrenreich, Hannelore
dc.creatorJahn, Olaf
dc.creatorKratzin, Hartmut D
dc.date2011-Jan
dc.date2015-11-27T13:22:16Z
dc.date2015-11-27T13:22:16Z
dc.date.accessioned2018-03-29T01:14:33Z
dc.date.available2018-03-29T01:14:33Z
dc.identifierProteomics. v. 11, n. 2, p. 261-9, 2011-Jan.
dc.identifier1615-9861
dc.identifier10.1002/pmic.201000371
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/21204253
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/199797
dc.identifier21204253
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1300030
dc.descriptionThe molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level.
dc.description11
dc.description261-9
dc.languageeng
dc.relationProteomics
dc.relationProteomics
dc.rightsfechado
dc.rightsCopyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
dc.sourcePubMed
dc.subjectAdult
dc.subjectAmino Acid Sequence
dc.subjectAntipsychotic Agents
dc.subjectApolipoprotein A-i
dc.subjectBiological Markers
dc.subjectBipolar Disorder
dc.subjectFemale
dc.subjectHumans
dc.subjectLithium Compounds
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMolecular Sequence Data
dc.subjectProteome
dc.subjectSpectrometry, Mass, Matrix-assisted Laser Desorption-ionization
dc.titleApolipoprotein A-i As A Candidate Serum Marker For The Response To Lithium Treatment In Bipolar Disorder.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución